According to new research published in European Journal of Neurology, susceptibility to multiple sclerosis may be predicted by looking at individuals’ protein profiles, otherwise known as proteomes. A team led by principal investigator Dr. S. Jacobson at the National Institutes of Health and Dr. M. T.
Fingolimod is a disease modifying therapy (DMT) used to treat relapsing remitting multiple sclerosis (RRMS) patients as well as patients who continue to present with relapses despite treatment with beta interferon drugs, and is the first oral medication to be approved by the U.S. Food and Drug…
Biogen Idec, a biotechnology company focused on developing innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders, has announced that the U.S. Food and Drug Administration (FDA) has approved PLEGRIDYTM (peginterferon beta-1a), a new treatment for people with relapsing forms of multiple sclerosis…
New Zealand and Australian-based biotechnology company Innate Immunotherapeutics recently announced that it has begun to recruit patients with Secondary Progressive Multiple Sclerosis (SPMS) for its phase 2B trial of its experimental therapy MIS416. The study, which will be administered by the Western Australian…
Welsh health minister Mark Drakeford has announced that Wales has become the first UK country to authorize a cannabis-based medicine under its National Health Service. Sativex, a proprietary oral spray cannabinoid medicine that has been licensed in the UK to treat muscle spasms and stiffness in people…
While the majority of scientists dedicated to multiple sclerosis research focus on genetic regulators of conditions such as autoimmunity, demyelination, inflammation, and neurodegeneration, a team from the University of Lubeck in Germany, led by Saleh M. Ibrahim, MD, PhD, focuses on genetic regulators of conduction velocity. The team is uncovering…
Just yesterday, the President of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), Suhayl Dhib-Jalbut, publicly announced the details of this year’s MSBoston2014 conference, in collaboration with the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). According to Dhib-Jalbut — who is also the…
Regulus Therapeutics, Inc., a San Diego-based biopharmaceutical company that specializes in the research and development of experimental drugs that target microRNAs, recently announced that it has signed a contract to work together with Biogen Idec. Under Regulus’ microMarkers™ project, the two companies will be collaborating on research efforts to…
Researchers have recently discovered that the fatigue that patients with multiple sclerosis (MS) experience is not the same kind of fatigue that healthy people feel from time to time, nor is it caused by the same factors. The National Multiple Sclerosis Society reports that around 80% of people who suffer from…
Multiple sclerosis (MS) patients who are prescribed Tysabri have an increased risk to develop the rare, often fatal infection of the brain called progressive multifocal leukoencephalopathy (PML), according to a recent study. PML is caused by a common virus that infects blood cells and can be mobilized by popular RRMS drug Natalizumab,…
A new stem cell transplant therapy may offer patients with multiple sclerosis (MS) an alternative treatment option. According to a recent report on KCBD by Kasie Davis, researchers are pointing to the success of an MS patient named Dan Tiel, who had been reduced to living in a wheelchair due to…
The common symptom of fatigue experienced by multiple sclerosis (MS) patients may be caused by regional damage in the brain, according to research conducted at the Vita-Salute San Raffaele University in Italy and published in the journal Radiology. Scientists analyzed atrophies and lesions in the white matter and grey matter of 65…
According to a study published in the Journal of Neurology Neurosurgery & Psychiatry, HIV infection is correlated to a significantly lower risk of developing multiple sclerosis (MS). The researchers analyzed a previous report by a team of Danish researchers whereby an HIV positive man with MS had his symptoms…
Findings of a number of scientific research articles, reviewed in a recent article from researchers at University of Bari and National Cancer Institute in Italy, describe a common response to injury in multiple sclerosis patients and animal models of experimental allergic encephalomyelitis (EAE). The response, known as…
Australian authorities are alerting Multiple Sclerosis patients to the risk of unproven stem cell treatments that are being performed both in the country and overseas, after the recent death of a woman in Russia undergoing a controversial treatment for the disease. The continued marketing campaigns to…
Synthetic Biologics, Inc., a biotechnology company developing novel drug candidates targeting specific pathogens that cause serious infections and diseases, announced that its latest data on Trimesta™, regarding cognitive and disability measures in women suffering from multiple sclerosis (MS), will be presented at the 2014 Joint Americas and European Committees…
Scientists at The New York Stem Cell Foundation (NYSCF) Research Institute have made encouraging advances in the development of a viable cell replacement therapy for multiple sclerosis using a patient’s own cells, known as induced pluripotent stem cells (iPSCs). Since multiple sclerosis is a chronic demyelinating disease of unknown…
In spite of an eight week delay, New Zealand-based Innate Immunotherapeutics is still planning to enroll patients for its phase 2b clinical trial that will study the experimental drug MIS416 for secondary progressive MS. The clinical research organization (CRO) involved in the management of the trial informed the company about the…
The European Commission granted marketing authorization for the use of Plegridy, a drug developed by Biogen Idec as a treatment for adults with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS). The approval comes at a time when…
Complementary and alternative medicine (CAM) are no substitutes for the regular treatment of multiple sclerosis (MS), however, they are becoming more common among patients as a way of alleviating the symptoms of the disease. Massage therapy is an example of that. 36-year-old Jessica Rich is a patient who embraced…
The U.S. Food and Drug Administration (FDA) recently notified Concert Pharmaceuticals that the company had fulfilled all necessary preclinical toxicological tests for the oral therapy CTP-354 for the treatment of multiple sclerosis, spinal cord injury, and spasticity. The authorization to administer repeated doses of the compound, in excess of 6 mg per day,…
For the approximately 15-20% of multiple sclerosis patients with acute optic neuritis (AON), lack of vitamin D may be partly responsible. A new study published in Neurology identified a link between vitamin D levels and AON severity. Individuals with higher vitamin D levels may experience less severe…
A Ph.D. student at the University of Southern California (USC) Viterbi Ming Hsieh Department of Electrical Engineering, Kun Yue, is developing a model of selected brain circuits to study multiple sclerosis (MS) in an effort to develop a nanotechnology based treatment for the disease. Yue believes that new technology can lead…
The next Bike Multiple Sclerosis Cactus and Crude event, a bike run hosted by the National MS Society to raise awareness on this disease, will take place this weekend at the starting line in Midland, TX gathering 200 to 250 cyclists that will ride a total of…
The UK’s National Institute for Health and Care Excellence (NICE) gave a positive final appraisal determination to the use of the Biogen Idec‘s drug Tecfidera (dimethyl fumarate) in adults for the treatment of relapsing-remitting multiple sclerosis (RRMS), having turned back on their preliminary negative recommendation. The oral…
Alkermes plc is looking to add one more treatment to the repertoire for multiple sclerosis drugs by initiating a Phase 1 clinical trial study of ALKS 8700. This novel molecule, developed by Alkermes, will be evaluated for safety, tolerability, and pharmacokinetics. “We expect the results of this study to…
Eight new drugs that are able to stimulate the nervous system were discovered by a research team at UC San Francisco recently. The team utilized a novel screening platform and examined the cellular effects of 1,000 chemical compounds. The scientists believe the discovery may impact the treatment of the tissue…
Startup biotech company ImStem Biotechnology is looking to raise additional funding for their upcoming clinical trials after publishing promising research on a unique stem-cell treatment used on mice with multiple sclerosis. The company has already received previous funding…
The Scottish Medicines Consortium (SMC) announced the approval of the drug Lemtrada, produced by Genzyme, for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) and active disease defined by clinical or imaging features, within the national health system (NHS) in Scotland. Lemtrada…
The American Public Broadcasting Service (PBS) recently aired a documentary about a University of Central Oklahoma (UCO) music professor, who suffers from multiple sclerosis (MS), on OETA. “Healed: Music, Medicine and Life with MS,” tells the story of Jim Klages‘s struggle against the disease. Klages was an accomplished musician and…
Get regular updates to your inbox.
